A subset of women with recurrent or advanced endometrial cancer, whose disease progressed on or after platinum-based chemotherapy, achieved clinically meaningful responses after treatment with dostarlimab, results of a Phase 1 clinical trial show. The findings, “Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer,” were presented in a webinar as part of the Society of Gynecologic Oncology’s 2020 virtual congress. Dostarlimab (formerly known as TSR-042) is…
May 06, 2020May 6, 2020